Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

  • Joana Ferra Pneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
  • Filipa Mousinho Hematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
  • Francisca Miranda Hematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
  • Sandra André Pneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
  • Celina Afonso Hematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
  • Fernando Nogueira Pneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., Portugal
DOI: https://doi.org/10.12890/2021_002345

Keywords

Primary effusion lymphoma, brentuximab vedotin, non-HIV

Abstract

Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission.

VIEW THE ENTIRE ARTICLE

References

  • Narkhede M, Arora S, Ujjani C. Primary effusion lymphoma: current perspectives. Onco Targets Ther 2018;11:3747–3754.
  • Okada S, Goto H, Yotsumoto M. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res 2014;3(3):65–74.
  • Klepfish A, Sarid R, Shtalrid M, Shvidel L, Berrebi A, Schattner A. Primary effusion lymphoma (PEL) in HIV-negative patients - a distinct clinical entity. Leuk Lymphoma 2001;41(3–4):439–443.
  • Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood 2013;122(7):1233–1242.
  • Chang VA, Wang HY, Reid EG. Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. Blood 2019;3(5):766–768.

    • Published: 2021-02-22

    Issue: 2021: Vol 8 No 2 (view)

    Section: Articles

    How to cite:
    1.
    Ferra J, Mousinho F, Miranda F, André S, Afonso C, Nogueira F. Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma. EJCRIM 2021;8 doi:10.12890/2021_002345.

    Most read articles by the same author(s)